Anna Hecht de Gutierrez

Anna Hecht de Gutierrez, M.D., Ph.D.

  • Assistant research professor and visiting scholar, Department of Systems Biology

Anna Hecht de Gutierrez, M.D., Ph.D.

Anna Hecht de Gutierrez, M.D., Ph.D., is a physician and scientist focusing her work on the treatment and research of hematologic diseases.
 
Dr. Hecht de Gutierrez completed her studies at the Medical Faculty Mannheim of the University of Heidelberg in Germany and wrote her “summa cum laude” rated doctorate on the topic of molecular risk stratification in acute promyelocytic leukemia.
 
From 2013 to 2016, she worked as a resident physician and scientist in the Department of Hematology and Oncology at the University Hospital Mannheim with Professor W.K. Hofmann. Dr. Hecht de Gutierrez is a former scholar of the “Studienstiftung des deutschen Volkes,” or the German National Merit Foundation. For her doctorate she was awarded the Ludolf-Krehl-Prize of the Southwestgerman Society of Internal Medicine.
 
Currently, she is a scholar of the “Deutsche Forschungsgemeinschaft” (German Research Foundation), first working as a visiting assistant research professor in the laboratory of Markus Müschen, M.D., Ph.D., at the University of California San Francisco and now in the Department of Systems Biology at Beckman Research Institute of City of Hope.
  • Hecht A, Mezger J, Gnadler M, Lengfelder E. Very Severe Differentiation Syndrome in Low Risk Acute Promyelocytic Leukemia Treated with ATRA plus ATO - a Peril of Differentiating Therapy. Dtsch Med Wochenschr 2017 Jan;142(2):111-114.
  • Hecht A, Nowak D, Nowak V, Hanfstein B, Büchner T, Spiekermann K, Weiss C, Hofmann WK, Lengfelder E, Nolte F. A molecular risk score integrating BAALC, ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia. Leuk Res. 2015 
  • Hecht A, Nolte F, Nowak D, Nowak V, Reinwald M, Hanfstein B, Faldum A, Büchner T, Spiekermann K, Sauerland C, Weiss C, Hofmann WK, Lengfelder E. Prognostic Importance of Expression of the Wilms' Tumor 1 Gene in Newly Diagnosed Acute Promyelocytic Leukemia. Leuk Lymphoma. 2015 Jan 21:1-7.
  • Nolte F, Hecht A, Reinwald M, Nowak D, Nowak V, Hanfstein B, Faldum A, Büchner T, Spiekermann K, Sauerland C, Hofmann WK, Lengfelder E. In acute promyelocytic leukemia (APL) low BAALC gene expression identifies a patient group with favorable overall survival and improved relapse free survival. Leuk Res. 2013 Apr;37(4):378-82.
  • Hecht A, Nowak D, Nowak V, Hanfstein B, Faldum A, Büchner T, Spiekermann K, Sauerland C, Lengfelder E, Hofmann WK, Nolte F. High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia. Ann Hematol. 2013 Apr;92(4):443-9.
  • Nowak D, Klaumuenzer M, Hanfstein B, Mossner M, Nolte F, Nowak V, Oblaender J, Hecht A, Hütter G, Ogawa S, Kohlmann A, Haferlach C, Schlegelberger B, Braess J, Seifarth W, Fabarius A, Erben P, Saussele S, Müller MC, Reiter A, Buechner T, Weiss C, Hofmann WK, Lengfelder E. SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3. Genes Chromosomes Cancer. 2012 Aug;51(8):756-67.
     
Back To Top